Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme, a subsidiary of Sanofi-Aventis, has completed the expansion of its €150m biotechnology facility in Waterford, Ireland.
Subscribe to our email newsletter
The expansion is said to increase the plant’s capacity by three times and would help restore supply levels for some of its important medicines, inpharm.com reported.
The facility exports medicines to over 70 countries around the world.
Waterford site will take care of the US supplies of Genzyme’s rare disease drugs including Cerezyme (imiglucerase), Myozyme (alglucosidase alfa) for Pompe disease, Fabrazyme (agalsidase beta) for Fabry disease and Thyrogen (thyrotropin alfa) for post-operative thyroid cancer patients.